Fluoroquinolone antibiotics already carry warnings about the risks of QT prolongation and torsades de pointes, tendonitis and tendon rupture as well as central nervous system effects, including peripheral neuropathy and exacerbation of myasthenia gravis. The FDA had recently updated the labels to state that “the serious risks posed by fluoroquinolones generally outweigh their benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections that are treatable by other means.”

 

 

Here is an informative article posted today Dr.Josh Farkas on PulmCrit (EMCrit).

PulmCrit – Six reasons to avoid fluoroquinolones in the critically ill

 

Want to read more…?

 

May 5, 2016.  FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together

FDA updates warnings for fluoroquinolone antibiotics